Clinical trial

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-05-31

PhasePHASE3

Study timeline

Study start (actual)2018-05-31Date precision: day

Registry last updated2022-02-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Obstructive Pulmonary Disease (COPD)unresolved

Interventions

RevefenacinDRUG · verified · RxNorm: revefenacin

PlaceboDRUG

FormoterolDRUG · verified · RxNorm: formoterol

Sponsors & collaborators

Mylan Inc.lead sponsor

Theravance Biopharmacollaborator

Mapped research locations

MiamiFlorida, United States1 ColumbusOhio, United States1 TampaFlorida, United States1 OrlandoFlorida, United States1 GreenvilleSouth Carolina, United States1 SpartanburgSouth Carolina, United States1 SarasotaFlorida, United States1 MedfordOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03573817 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.